Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Revenue (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Revenue for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 77.83% year-over-year to $2.0 million, compared with a TTM value of $5.7 million through Dec 2025, down 73.28%, and an annual FY2025 reading of $29.1 million, down 11.19% over the prior year.
  • Revenue was $2.0 million for Q4 2025 at Roivant Sciences, up from $1.6 million in the prior quarter.
  • Across five years, Revenue topped out at $46.1 million in Q4 2021 and bottomed at $1.6 million in Q3 2025.
  • Average Revenue over 5 years is $15.0 million, with a median of $9.0 million recorded in 2024.
  • The sharpest move saw Revenue soared 957.22% in 2021, then plummeted 87.94% in 2024.
  • Year by year, Revenue stood at $46.1 million in 2021, then plummeted by 62.98% to $17.1 million in 2022, then skyrocketed by 117.8% to $37.1 million in 2023, then crashed by 75.72% to $9.0 million in 2024, then tumbled by 77.83% to $2.0 million in 2025.
  • Business Quant data shows Revenue for ROIV at $2.0 million in Q4 2025, $1.6 million in Q3 2025, and $2.2 million in Q2 2025.